Oncology Based Molecular Diagnostics Market To Reach $6.35 Billion By 2033

Oncology Based Molecular Diagnostics Market Growth & Trends

The global oncology based molecular diagnostics market size is expected to reach USD 6.35 billion by 2033, registering a CAGR of 5.5% from 2025 to 2033, according to a new report by Grand View Research, Inc. The rising geriatric population base, increasing global prevalence of cancer, rise in sedentary lifestyle adoption levels, and rising awareness & patient education are the driving forces for the oncology based molecular diagnostics market growth over the forecast period.

Growing prevalence of cancer patients owing to adoption of sedentary lifestyles and decrease in immunity levels are estimated to increase industrial growth rate. Furthermore, large variations in both cancer incidence and mortality rates in different sub-regions of developing countries such as Brazil, Mexico, South Africa, and India are also anticipated to enhance the usage of molecular diagnostics to increase survival rates by early detection and validation.

 Request a free sample copy or view report summary: Oncology Based Molecular Diagnostics Market Report

Oncology Based Molecular Diagnostics Market Report Highlights

• The breast cancer segment led the market with the largest revenue share of 18.69% in 2024.

• The reagents segment led the market with the largest revenue share by 58.61% in 2024, driven by their essential role in molecular diagnostic workflows across various cancer types.

• The polymerase chain reaction (PCR) technology segment led the market with the largest revenue share of 38.65% in 2024, due to its established role in detecting cancer-specific genetic mutations with high sensitivity and speed.

• North America dominated the oncology based molecular diagnostics market with the largest revenue share of 44.69% in 2024.

Oncology Based Molecular Diagnostics Market Segmentation

Grand View Research has segmented the global Oncology Based Molecular Diagnostics market on the basis of product, technology, type, and region:

Oncology Based Molecular Diagnostics Type Outlook (Revenue, USD Million; 2021 - 2033)

• Breast Cancer

• Prostate Cancer

• Colorectal Cancer

• Cervical Cancer

• Liver Cancer

• Lung Cancer

• Blood Cancer

• Kidney Cancer

• Others

Oncology Based Molecular Diagnostics Product Outlook (Revenue, USD Million; 2021 - 2033)

• Instruments

• Reagents

• Others

Oncology Based Molecular Diagnostics Technology Outlook (Revenue, USD Million; 2021 - 2033)

• PCR

• In situ hybridization

• INAAT

• Chips and microarrays

• Mass spectrometry

• Sequencing

• TMA

• Others

Oncology Based Molecular Diagnostics Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Oncology Based Molecular Diagnostics Market

• Abbott

• Bayer AG

• BD

• Cepheid

• Agilent Technologies, Inc.

• Danaher

• Hologic, Inc.

• Qiagen

• F. Hoffmann-La Roche Ltd.

• Siemens

• Sysmex